603983 丸美生物
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,459,31816.48%2,225,5941,731,7161,787,0291,744,989
减:营业总成本3,214,91723.17%2,030,1131,569,7701,522,8791,243,716
    其中:营业成本889,51913.89%652,222547,289643,037589,747
               财务费用(17,939)27.64%(14,391)(12,649)(35,818)(57,343)
               资产减值损失(3,288)-73.13%(13,051)(9,751)(11,463)(5,940)
公允价值变动收益433-144.01%70,9825,293611(2,571)
投资收益27,55337.60%43,64127,52524,66936,221
    其中:对联营企业和合营企业的投资收益23,790-5,387.68%--(1,381)(1,134)(112)
营业利润296,611-22.14%319,337207,337298,991572,525
利润总额295,731-22.31%317,086206,581309,625567,365
减:所得税费用48,98927.93%39,49739,15068,433103,969
净利润246,743-27.93%277,590167,431241,192463,396
减:非控股权益(496)-167.51%18,172(6,752)(6,729)(1,003)
股东净利润247,239-27.63%259,418174,183247,921464,399

市场价值指针
每股收益 (元) *0.620-27.06%0.6500.4300.6201.160
每股派息 (元) *0.500-33.33%0.5200.2500.1900.350
每股净资产 (元) *8.307-1.46%8.3477.942--7.426
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容